MDT

96.83

-2.02%↓

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

MDT

96.83

-2.02%↓

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

MDT

96.83

-2.02%↓

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

MDT

96.83

-2.02%↓

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

MDT

96.83

-2.02%↓

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

Home・Akcijų sąrašas・Adaptive Biotechnologies Corp

Adaptive Biotechnologies Corp

Uždarymo kaina

17.49 -1.19

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

17.39

Max

17.65

Pagrindiniai rodikliai
By Trading Economics
Pajamos	35M 9.5M
Pardavimai	35M 94M
Pelno marža	10.158
Darbuotojai	619
EBITDA	35M 17M

Rekomendacijos
By TipRanks
Rekomendacijos	Stiprus pirkimas
12 mėnesių prognozė	+15.58% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-02-10

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	147M 2.8B
Ankstesnė atidarymo kaina	18.68
Ankstesnė uždarymo kaina	17.49

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Very Strong Bullish Evidence

8.81 / 10.18 Palaikymas ir pasipriešinimas

Adaptive Biotechnologies Corp Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-01-16 23:29; UTC

Karštos akcijos

Stocks to Watch: Atossa Therapeutics, Union Pacific

2026-01-18 23:57; UTC

Įsigijimai, susijungimai, perėmimai

Elliott: Standalone Plan Offers Clear Path to Valuation of More Than Y40,000 a Share by 2028

2026-01-18 23:57; UTC

Įsigijimai, susijungimai, perėmimai

Elliott: Opposing Toyota Fudosan's Revised Tender Offer for Toyota Industries

2026-01-18 23:55; UTC

Rinkos pokalbiai

Oil Falls as Middle East Tensions Continue to Fade -- Market Talk

2026-01-18 23:40; UTC

Rinkos pokalbiai

Precious Metals Climb After Trump Threatens Europe With Tariffs Over Greenland -- Market Talk

2026-01-18 22:29; UTC

Rinkos pokalbiai

Miners Seen Extending Rally as Generalist Investors Warm to Sector -- Market Talk

2026-01-18 21:03; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-01-18 21:03; UTC

Rinkos pokalbiai

More Australian Voters Switch Away From Major Parties -- Market Talk

2026-01-18 19:46; UTC

Rinkos pokalbiai

FX Markets Taking Latest Trump Tariff Threat Calmly -- Market Talk

2026-01-17 15:06; UTC

Įsigijimai, susijungimai, perėmimai

Trump Purchased Netflix, Warner Bonds in Days After Deal Announcement -- Update

2026-01-17 03:10; UTC

Įsigijimai, susijungimai, perėmimai

Trump Purchased Netflix, Warner Bonds In Days After Deal Announcement -- WSJ

2026-01-16 22:48; UTC

Įsigijimai, susijungimai, perėmimai

Rail Regulator Sends $71.5 Billion Union Pacific-Norfolk Southern Deal Back for Redo -- 2nd Update

2026-01-16 22:43; UTC

Įsigijimai, susijungimai, perėmimai

Union Pacific: Additional Information Requested to Be Provided to Surface Transportation Board

2026-01-16 22:22; UTC

Įsigijimai, susijungimai, perėmimai

Rail Regulator Sends $71.5 Billion Union Pacific-Norfolk Southern Deal Back for Redo -- Update

2026-01-16 21:50; UTC

Rinkos pokalbiai

Įsigijimai, susijungimai, perėmimai

Tech, Media & Telecom Roundup: Market Talk

2026-01-16 21:50; UTC

Rinkos pokalbiai

Įsigijimai, susijungimai, perėmimai

Auto & Transport Roundup: Market Talk

2026-01-16 21:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2026-01-16 21:50; UTC

Rinkos pokalbiai

Health Care Roundup: Market Talk

2026-01-16 21:48; UTC

Rinkos pokalbiai

Įsigijimai, susijungimai, perėmimai

Union Pacific, Norfolk Southern Market Share Ruled as Faulty -- Market Talk

2026-01-16 21:41; UTC

Rinkos pokalbiai

Įsigijimai, susijungimai, perėmimai

Union Pacific, Norfolk Southern Deal Rejection Leaves Questions -- Market Talk

2026-01-16 21:38; UTC

Įsigijimai, susijungimai, perėmimai

Rail Regulator Sends $71.5 Billion Union Pacific-Norfolk Southern Deal Back for Redo -- WSJ

2026-01-16 21:30; UTC

Įsigijimai, susijungimai, perėmimai

STB: Union Pacific, Norfolk Southern Application Doesn't Include 'Projected Market Shares' as Required

2026-01-16 21:30; UTC

Įsigijimai, susijungimai, perėmimai

STB: Union Pacific, Norfolk Southern Application Doesn't Include Certain Schedules, Documents Expressly Made Part of Merger Agreement

2026-01-16 21:30; UTC

Įsigijimai, susijungimai, perėmimai

STB: Union Pacific, Norfolk Southern Application Doesn't Contain Certain Information Required by Regulations

2026-01-16 21:30; UTC

Įsigijimai, susijungimai, perėmimai

STB: Application Rejected Without Prejudice to Union Pacific, Norfolk Southern Refiling Revised Application Remedying Deficiencies

2026-01-16 21:30; UTC

Įsigijimai, susijungimai, perėmimai

Surface Transportation Board: Union Pacific, Norfolk Southern Major Merger Application Filed Dec. 19 Incomplete

2026-01-16 20:44; UTC

Uždarbis

5 Takeaways From This Season's Wealth Management Earnings -- Barrons.com

2026-01-16 20:42; UTC

Rinkos pokalbiai

Oil Futures Post Fourth Straight Weekly Gain -- Market Talk

2026-01-16 20:28; UTC

Rinkos pokalbiai

U.S. Natural Gas Slips Ahead of Long Weekend -- Market Talk

2026-01-16 19:12; UTC

Rinkos pokalbiai

Įsigijimai, susijungimai, perėmimai

Netflix Could Comment on Structure of Warner Bid During 4Q Results -- Market Talk

Akcijų palyginimas

Kainos pokytis

Adaptive Biotechnologies Corp Prognozė

Kainos tikslas

By TipRanks

15.58% į viršų

12 mėnesių prognozė

Vidutinis 20.25 USD 15.58%

Aukščiausias 21 USD

Žemiausias 20 USD

Remiantis 6 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Adaptive Biotechnologies Corp kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

6 ratings

Pirkti

Laikyti

Parduoti

Remiantis 6 analitikų, pateikusių Adaptive Biotechnologies Corp akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

8.81 / 10.18Palaikymas ir pasipriešinimas

Recent bullish events outweigh bearish events.

All events are bullish.

There is one bullish event.

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Adaptive Biotechnologies Corp

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.